New research suggests that atogepant, a calcitonin gene−related peptide receptor antagonist, may work immediately to prevent migraines.
The study, published online in Neurology, (2025 Jan 28;104(2):e210212) shows that patients treated with atogepant were less likely to experience a migraine on the first day of medication than those treated with a placebo. This group also had fewer migraines during each of the first four weeks of the study and fewer migraines during the entire 12-week